GVOKE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Gvoke, and when can generic versions of Gvoke launch?
Gvoke is a drug marketed by Xeris and is included in one NDA. There are two patents protecting this drug.
The generic ingredient in GVOKE is glucagon. There are twelve drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the glucagon profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Gvoke
A generic version of GVOKE was approved as glucagon by FRESENIUS KABI USA on May 8th, 2015.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for GVOKE?
- What are the global sales for GVOKE?
- What is Average Wholesale Price for GVOKE?
Summary for GVOKE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Prices: | Drug price information for GVOKE |
| DailyMed Link: | GVOKE at DailyMed |
US Patents and Regulatory Information for GVOKE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xeris | GVOKE HYPOPEN | glucagon | SOLUTION;SUBCUTANEOUS | 212097-003 | Sep 10, 2019 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Xeris | GVOKE PFS | glucagon | SOLUTION;SUBCUTANEOUS | 212097-001 | Sep 10, 2019 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Xeris | GVOKE HYPOPEN | glucagon | SOLUTION;SUBCUTANEOUS | 212097-004 | Sep 10, 2019 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Xeris | GVOKE PFS | glucagon | SOLUTION;SUBCUTANEOUS | 212097-002 | Sep 10, 2019 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Xeris | GVOKE HYPOPEN | glucagon | SOLUTION;SUBCUTANEOUS | 212097-003 | Sep 10, 2019 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Xeris | GVOKE HYPOPEN | glucagon | SOLUTION;SUBCUTANEOUS | 212097-004 | Sep 10, 2019 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
